Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III open-label single-arm study of two doses of nirsevimab in high-risk infants in Japan
2025-000021-13Phase 3
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nirsevimab in respiratory syncytial virus disease (RSV), sponsored by AstraZeneca. Primary endpoint: Incidence of treatment-emergent adverse events and other safety events.
02
Drugs
nirsevimab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2025-000021-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-000021-13.